<div id="readability-page-1"><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>Eli Lilly and Company, Pfizer, Bristol Myers Squibb, AbbVie, Gemini Therapeutics, Novo Nordisk A/S,  and Cytokinetics are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are publicly traded shares of companies that research, develop, manufacture, and sell prescription drugs, vaccines, and related medical products. For investors, these stocks are driven by clinical-trial results, regulatory approvals, patent lifecycles, and healthcare policy, which can create substantial growth potential but also high volatility and risk. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p>Read Our Latest Research Report on LLY</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><ul><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p>Read Our Latest Research Report on PFE</p><h2>Bristol Myers Squibb (BMY)</h2><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p><p>Read Our Latest Research Report on BMY</p><h2>AbbVie (ABBV)</h2><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><p>Read Our Latest Research Report on ABBV</p><h2>Gemini Therapeutics (GMTX)</h2><p>Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.</p><p>Read Our Latest Research Report on GMTX</p><h2>Novo Nordisk A/S (NVO)</h2><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><p>Read Our Latest Research Report on NVO</p><h2>Cytokinetics (CYTK)</h2><p>Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.</p><p>Read Our Latest Research Report on CYTK</p><h2>Further Reading</h2><ul><li>MarketBeat's Top Five Stocks to Own in December 2025</li><li>RKLB, ASTS, TDG: Insiders are Selling These 3 Space Stocks</li><li>Instacart Got Caught Surveillance Pricing... But Investors Didn't Care</li><li>Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength</li><li>Amazon Now Delivery Push Could Boost Its 2026 Outlook</li><li>5 Small-Cap Stocks to Watch in 2026 as Investors Rotate Out of Big Tech</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>MarketBeat's stock screener tool highlights seven pharmaceutical stocks to watch: Eli Lilly, Pfizer, Bristol Myers Squibb, AbbVie, Gemini Therapeutics, Novo Nordisk, and Cytokinetics. These stocks are driven by clinical-trial results, regulatory approvals, and healthcare policy, offering growth potential but also high volatility. Eli Lilly, Pfizer, and Bristol Myers Squibb have recently raised dividends, signaling strength. Investors should consider these stocks for their potential upside.</p>

Top Pharmaceutical Stocks To Follow Now - December 22nd